3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other neoplasm
1
Gynecologic
1
Conditions
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Thymoma
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Uterine Prolapse
1
Prostatic Neoplasms
1
Prostatic Diseases
1
Precancerous Conditions
1
Pelvic Organ Prolapse
1
Ovarian Neoplasms
1
Obesity, Morbid
1
Myasthenia Gravis
1
Menstruation Disturbances
1
Mediastinal Neoplasms
1
Leiomyoma
1
Hernia, Ventral
1
Hernia, Inguinal
1
Genital Diseases, Female
1
Endometriosis
1
Colonic Neoplasms
1
Adenomyosis
1
Interventions
Paclitaxel
113
Carboplatin
99
Bevacizumab
59
pembrolizumab
56
liposomal doxorubicin
56
Gemcitabine
42
olaparib
39
Topotecan
33
niraparib
29
Nivolumab
21
Cisplatin
21
Doxorubicin
17
Cyclophosphamide
17
1-dodecylpyridoxal
16
Drug Therapy
15
Docetaxel
15
avelumab
13
Fulvestrant
11
oregovomab
10
Oxaliplatin
10
rucaparib
9
fludarabine
9
Injections
9
Fluorouracil
9
veliparib
8
mirvetuximab soravtansine
8
atezolizumab
8
Cetuximab
8
fluzoparib
7
cemiplimab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ovarian Neoplasms
×
Robotic Surgical Procedures
×
Clear all
NCT07120945
2026-06-02
Embrace Gyn
Medtronic - MITG
Phase NA
Active not recruiting
70 enrolled